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Abstract
INTRODUCTION—High blood glucose levels may be responsible for the increased risk for 
dementia in diabetic patients.
METHODS—A secondary data analysis merging electronic medical records (EMRs) with data 
collected from the Indianapolis-Ibadan Dementia project (IIDP). Of the enrolled 4105 African 
Americans, 3778 were identified in the EMR. Study endpoints were dementia, mild cognitive 
impairment (MCI) or normal cognition. Repeated serum glucose measurements were used as the 
outcome variables.
RESULTS—Diabetic participants who developed incident dementia had a significant decrease in 
serum glucose levels in the years preceding the diagnosis compared to the participants with normal 
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cognition (p=0.0002). They also had significantly higher glucose levels up to nine years before the 
dementia diagnosis (p=0.0367).
DISCUSSION—High glucose levels followed by a decline occurring years prior to diagnosis in 
African American participants with diabetes may represent a powerful pre-symptomatic metabolic 
indicator of dementia.
Keywords
Dementia; Alzheimer disease; longitudinal risk factors; diabetes; glucose levels; African 
Americans; electronic medical records; early detection
1. Introduction
With the aging of the US and world populations, the dementing disorders including 
Alzheimer disease (AD) are emerging as a major public health challenge. The identification 
of potentially modifiable risk factors for these disorders is critically important. Vascular risk 
factors such as diabetes, hypertension, hyperlipidemia, and obesity have been implicated as 
risk factors for dementia but the results have not been consistent [1–4].
Rates of diabetes have been increasing worldwide [5] thus the relationship between diabetes 
and dementia has received particular scrutiny [6–10]. A recent longitudinal study 
demonstrated that higher glucose levels in elderly participants with or without diabetes were 
associated with an increased risk of dementia occurring years before the dementia diagnosis 
[11].
Most predictive studies of the association of vascular risk factors with dementia have 
typically utilized measurements at a single point of time or relied on a mean value of 
multiple measurements over time. These analytic approaches may fail to capture change or 
variability in these markers over the lengthy pre-symptomatic period that precedes a clinical 
diagnosis of dementia/AD [12].
The Indianapolis Ibadan dementia project (IIDP) is a 20 year National Institute on Aging-
funded longitudinal study of dementia and its risk factors in elderly community-dwelling 
African Americans living in Indianapolis, Indiana and elderly community-dwelling Yoruba 
living in Ibadan, Nigeria. Recently, data from the African American participants in the study 
were merged with data from the Indiana Network for Patient Care, a regional health 
information exchange, allowing us to examine longitudinal vascular risk factor profiles 
based on diagnostic testing obtained in the routine care of these older adults. This paper 
reports on an analysis of repeated serum glucose measurements and cognitive outcomes for 
the African American participants.
2. Methods
2.1 Study Population
The study population consisted of the African American participants of the IIDP. All were 
age 65 or older residing in Indianapolis, Indiana. Recruitment was conducted at two time 
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points. During the first recruitment in 1992, 2212 African Americans age 65 or older living 
in Indianapolis were enrolled. In 2001, the project enrolled 1893 additional African 
American community-dwelling participants 70 years and older. All participants agreed to 
undergo regular follow-up cognitive assessment and clinical evaluations. Details on the 
assembling of the original cohort and the enrichment cohort are described elsewhere [13, 
14].
The study followed a two stage design with a screening evaluation every two to three years 
followed by a more comprehensive home based clinical evaluation. Diagnoses of dementia, 
mild cognitive impairment, and Alzheimer disease were made by consensus [15–17]. For 
more details of the diagnostic process and criteria see eMethods 1 in the Supplement.
2.2 Electronic Medical Records
Electronic medical records were obtained from the Indiana Network for Patient Care 
(INPC). The INPC is a regional health information exchange that integrates clinical 
information from the five major health care systems in Indianapolis in support of medical 
care (see eMethods 2 in Supplement)[18].
EMR data were made available after appropriate approvals from the INPC Privacy Board. Of 
the 4105 participants enrolled in IIDP, 3778 (92%) were identified in INPC using social 
security numbers, name, gender and date of birth. For each individual, we retrieved serum 
glucose and hemoglobin A1c measures associated with outpatient visits, ICD-9 codes for 
diabetes and common comorbidities, and the use of diabetes medications classified as 
insulin only, oral antidiabetic medication only, or both insulin and oral medications. In 
addition, ICD-9 codes were used in the EMR to define diabetes complications [19].
3. Statistical Analyses
Since our analysis is focused on the change in glucose levels, repeated glucose measures 
were used as the outcome variables. Three groups of participants were defined in the 
analysis. The first group consisted of participants with incident dementia diagnosed at or 
after the 1995 evaluation for those in the original cohort and after the 2001 evaluation for 
participants enrolled in 2001. A second group consisted of participants diagnosed with MCI 
at their last evaluation. The third group consisted of participants who were either diagnosed 
as normal or were determined to have good cognitive function at their last follow-up 
evaluation. Since we are interested in the within-person changes in glucose levels prior to 
dementia diagnosis, only participants with at least two glucose measures before reaching 
IIDP study endpoints are included in this analysis. Participants with one or no glucose 
measure or those diagnosed with dementia prior to their first glucose measures were 
excluded from the analysis. This analysis included 1991 participants with longitudinal 
glucose values who contributed a total of 22865 glucose measures, where the glucose values 
were daily averaged glucose values and 1630 of the glucose values were calculated from 
hemoglobin A1c values (28.7*hemoglobin A1C-46.7) as done in previous studies [11].
To compare changes in serum glucose levels prior to the clinical diagnosis of dementia or 
MCI to those in normal participants, we aligned the timing of the glucose measurements to 
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an index time point defined to be the time of diagnosis for participants with incident 
dementia and the time of last evaluation for normal participants. As participants with MCI in 
our cohort have heterogeneous outcomes, we included only those who were diagnosed with 
MCI at their last evaluation in the MCI category allowing those whose diagnosis had 
changed to normal or dementia to be included in the respective categories. Therefore, 
glucose measures taken during the course of the study were aligned by the number of years 
serum glucose was measured prior to the index time. In all of our statistical models, index 
time was coded as time zero. For example, a participant with serum glucose measured at 
1995 and a diagnosis of dementia in 2007 would have time coded as -12, indicating that 
glucose was measured 12 years prior to the dementia diagnosis.
Demographic characteristics and medical history among the three groups were compared 
using chi-square tests for categorical variables and analysis of variance (ANOVA) for 
continuous variables. Covariates considered for the mixed effects models included baseline 
age, gender, years of education, alcohol, smoking, BMI, systolic and diastolic pressure, 
history of hypertension, coronary heart disease, stroke, cancer and depression based on self 
or informant reports collected from IIDP evaluations. ICD-9 codes from EMR were used to 
classify participants into those with diabetes or no diabetes. Two additional covariates based 
on EMR data were included as covariates: renal disease was identified with blood creatinine 
levels ≥2 mg/dL or ICD-9 codes for nephropathy [19], hypoglycemia was defined as any 
glucose measure ≤70 mg/dL.
We first explored separate single covariate mixed effect models with repeated glucose 
measures as the dependent variables and including one covariate, main effect of time and 
time squared, and an interaction term between the covariate and time. The final multivariate 
model included variables that had either significant main effects or significant interaction 
with time in the single covariate glucose models in addition to group, time and the 
interaction between group and time. Significant interactions between group and time would 
indicate differences in changes of glucose levels over time among the three groups. We also 
examined interactions between group and time squared and found these higher order 
interactions to be nonsignificant. The mixed effects models were first examined in all 
participants with an interaction among group, time and diabetes status (yes versus no) which 
resulted in a significant interaction (p=0.0010). Therefore, the mixed effects models were 
conducted separately in participants with diabetes and those without diabetes based on the 
same set of covariates. The final multivariate models included only covariates with either 
significant main effect or significant interactions with time. Post-hoc analyses examining 
glucose differences among the three groups at each year prior to the index time were 
conducted using linear contrasts within the final mixed effect model.
Additional sets of mixed effects models in participants with diabetes were conducted. The 
multivariate mixed effects model was used in participants with Alzheimer’s disease (AD), 
MCI and normal cognition, excluding those with non-AD dementia. The final model was 
also used in a subset of the analysis sample by excluding participants with cerebrovascular 
disease. To determine whether the decline in glucose levels in participants with incident 
dementia was accounted for by decline in BMI or albumin levels, we also conducted mixed 
effects models with repeated BMI and albumin levels measured during study follow-up as 
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time-varying covariates (see eStatistical Analysis in Supplement). We also compared the 
demographic characteristics and medical conditions between participants included in the 
analyses and those excluded due to the lack of two or more glucose measures in the 3778 
participants identified in EMR. The statistical software SAS version 9.4 was used for the 
analyses.
4. Results
A total of 1991 individuals with two or more serum glucose measures were included in this 
analysis. There were 207 participants diagnosed with dementia (163 with AD) during the 
course of the study, 211 with MCI at their last evaluation, and 1573 participants who 
remained in the normal group at their last evaluation. Median length of follow-up was 7.6 
years (interquartile range: 4.3, 11.1), with the MCI participants having a longer median 
follow-up (9 years) than those in the group with dementia (7.2 years) or the normal group 
(7.4 years). The mean number of serum glucose measures per year is 1.1 and the three 
groups did not differ in the number of glucose measures over the study follow-up period 
(p=0.8669).
Demographic characteristics and comorbidities by the three groups are presented in Table 1. 
The three groups differed in baseline age, years of education, BMI, history of smoking, 
stroke and diabetes. Among the subset of the cohort (n=1255) genotyped for APOE, there 
was a significantly higher percentage of APOE ɛ4 carriers in the group with dementia 
(52.4%), followed by the group with MCI (40.3%) and the normal group (31.0%; p<0.0001). 
In participants with diabetes, there were no significant differences between the three groups 
in the percentage of participants treated with insulin (p=0.3439).
In Table 2, we present results from the mixed effects model with repeated glucose measures 
as the outcome variable in participants who do not have diabetes. There was no significant 
group and time interaction indicating that changes in glucose over time did not differ among 
the three groups. In Table 3, results of the mixed effects model for glucose in participants 
with diabetes are presented. Participants who had dementia had a significant decrease in 
glucose compared to participants with MCI and those who were normal while participants 
with MCI did not differ from those in the normal group adjusting for gender, age at baseline, 
BMI and diabetic medications. Figure 1 illustrates the differences in glucose levels over time 
for participants in the three groups. Participants with incident dementia had significantly 
higher glucose levels than those with MCI and in the normal group many years before their 
diagnosis. However, with the steady decrease in glucose levels over time for participants 
with dementia, glucose levels appeared similar among the three groups within three years of 
index time which was the time of diagnosis for participants with dementia and the last 
evaluation time for the rest of the participants.
In Table 4, we compared the rates of diabetes complications among participants with 
dementia, MCI and normal groups using ICD-9 codes from the EMR following the 
classifications published previously.[19] Participants with diabetes who were diagnosed with 
dementia during follow-up had significantly higher rates of cerebrovascular disease (35.9%) 
than those who were diagnosed with MCI (12.7%) or those in the normal group (12.1%). 
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There were no significant differences in the rates of other complications among the three 
groups (p=0.4671). The three groups also did not differ in the total numbers of other 
complications (p=0.1042).
Additional analyses restricting the dementia group to AD or excluding those with 
cerebrovascular disease revealed similar but less steep decreases in glucose level in the 
group without cerebrovascular disease or with AD (see eTables 1 and 2). Further analyses 
accounting for changes in BMI or albumen levels (see eResults, eTables 3 and 4 and 
eFigures 1 and 2) indicate that the decrease in glucose levels in dementia participants was 
independent of changes in BMI (see eResults and eTable 5). Comparisons of characteristics 
between participants included in the analyses and those excluded due to lack of glucose 
measures are also included. The 1787 participants excluded from the study tended to be 
men, have less education, but with lower rates of co-morbidities including diabetes (see 
eTable 6).
5. Discussion
In this analysis using repeated glucose measures obtained up to 18 years before the 
diagnosis of dementia, we found that among participants with diabetes, those who develop 
incident dementia had higher glucose levels compared to those who develop MCI or those 
with normal cognition. We also found that among the participants with diabetes, those who 
developed incident dementia experienced a significant decline in glucose levels in the years 
prior to the dementia diagnosis compared to participants with MCI and normal participants.
Our finding of an association between high glucose levels and increased risk of dementia is 
similar to that reported by Crane et al but in our study the association was confined only to 
those participants with diabetes. The reason for this discrepancy is unclear. Our population 
was African American. Differences in glucose homeostasis have been reported between 
African American and white populations and the rates of diabetes are higher in African 
Americans [20, 21]. In our study 48.9% of the participants had diabetes as compared to 
<10% in the Crane study. A statistically significant relationship with high glucose levels and 
dementia risk persisted in the participants with diabetes until at least nine years prior to 
diagnoses in our study. The Seattle group reported a significant relationship up to 5–8 years 
prior to diagnosis. This difference may be attributable to the differences in statistical 
methods used between the studies.
Perhaps the most striking finding from this study was the highly significant decline in 
glucose levels that occurred in the participants with diabetes in the years prior to the 
diagnosis of dementia but not in participants that were adjudicated with MCI or no cognitive 
impairment. We could find no published study that reported similar findings using the 
innovative analytic methodology we applied. One possible explanation for these findings is 
that the severe hyperglycemia, which in previous reports has been associated with increased 
risk for dementia perhaps by accelerating brain macrovascular disease [11], also induces 
direct neuronal damage [22]. This direct effect on neurons and glia could impair regions of 
the brain such as the hypothalamus and other medullary regions and disrupt central 
pathways related to hypoglycemia awareness or glucose counter regulatory responses. Our 
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results are consistent with the findings of Brinton and her colleagues suggesting there is a 
shift in the brain metabolic profile from a glucose-driven to a less efficient ketogenic 
pathway at least in elderly women [23]. It is also possible that physicians when confronted 
with high glucose levels increased the number or dosage of anti-diabetic medications. We 
found no significant differences in types of anti-diabetic medication used between the 
groups, and no increased use of insulin in the group that developed dementia. However, 
there could have been dose differences within the same medication types that were not 
captured in our analysis.
In a previous paper we reported a significantly increased risk for cognitive decline in our 
African American participants with diabetes and that this appeared to be mediated primarily 
by increased levels of cerebrovascular pathology, particularly incident stroke, in the diabetic 
participants [16]. In this analysis, when the rates of possible diabetic complications were 
compared among the three groups, only cerebrovascular disease was significantly higher in 
the group of participants with incident dementia. When participants with cerebrovascular 
disease are excluded from the study, the association between change in glucose levels and 
dementia weakened (see eTable 2). When the analyses are limited to participants with 
probable and possible AD, the association between dementia and change in glucose levels 
also become non-significant (see eTable 1). These findings do support the hypothesis that 
the association between high and subsequently declining glucose levels and dementia are 
mediated to a significant degree by increased levels of cerebrovascular disease in these 
participants.
Results from other studies have also suggested an early effect on metabolic homeostatic 
mechanisms during the dementing process. In a prior analysis we reported a similar finding 
with declining BMI levels in participants who developed dementia [24]. Mielke et al 
reported that both declining cholesterol levels and declining BMI were associated with 
incident dementia, and suggested that this finding may be related either to brain pathology 
occurring in the hypothalamus area, or to reduction of appetite caused by incipient dementia 
symptoms such as apathy and depression [25]. In an attempt to explore this latter possibility 
we also included BMI levels and albumin levels in our analysis. BMI levels but not albumin 
levels showed a significant difference in decline between participants with incident dementia 
and those in the other diagnostic groups (see eTables 3 and 4 and eFigures 1 and 2). When 
changes in BMI are incorporated into the models the decline in glucose levels remained in 
participants with incident dementia (see eTable 5). This finding, together with the lengthy 
pre-dementia time period of the changes, supports the suggestion by Meilke et al that these 
changes are related to brain pathology rather than being a product of apathy or depression. 
The fact that no decline in glucose levels was detected in participants with MCI might 
appear to contradict this hypothesis, but in our study MCI outcomes were very 
heterogeneous. The MCI participants who subsequently developed dementia are included in 
our dementia subgroup.
In summary, the results of these analyses add to accumulating evidence that high glucose 
levels are associated with an increased risk for dementia and that this risk accrues over many 
years prior to a dementia diagnosis in participants with diabetes. We also report that after a 
period of elevated serum glucose levels, these levels decline significantly as the patient 
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progresses toward a clinical diagnosis of dementia. This decline in glucose levels together 
with a decline in BMI may well represent a powerful pre-symptomatic metabolic indicator 
for future dementia in participants with diabetes. A similar pattern of changes in blood 
pressure in the period preceding dementia have also been reported. These potential 
metabolic changes could be due to the underlying pathology leading to dementia or may 
directly contribute to this pathology. It will be important to investigate in the future whether 
interventions that alter these metabolic changes offer a pathway for prevention of dementia.
5.1 Strengths
The current study has a number of strengths. The participants represent a well-characterized 
community-based random sample of elderly African Americans who received standardized 
clinical assessments and consensus- based clinical diagnoses using the same diagnostic 
criteria over time. The follow up period was lengthy. The use of EMR allowed the access to 
repeated laboratory measures associated with outpatient visits. Although many research 
studies have measured glucose as part of biomarker panel, few have the resources to support 
the collection of repeated biomarker measures.
5.2 Limitations
This analysis was confined only to those participants with repeated glucose level 
measurements which was approximately 50% of the total sample. The 1787 participants 
excluded from the study tended to be men, have less education, but with lower rates of co-
morbidities including diabetes which may explain the lack of repeated glucose measures (see 
eTable 6).
It was not possible from our database to distinguish between fasting and non-fasting glucose 
levels nor did this analysis include estimates of glucose variability which has also been 
proposed as an independent risk factor for diabetic complications including dementia. 
Information on antidiabetic drug dosage was not available for this analysis.
Reports from previous studies have suggested that midlife rather than late life diabetes is a 
risk factor for dementia and that longer duration is associated with greater risk [28, 29]. 
Unfortunately our electronic medical record system, which was unable to capture midlife 
data for all participants in our cohort, did not allow us to address this issue.
As mentioned previously our population is African Americans who have reported higher 
rates of diabetes and differences in glucose metabolism as compared to white populations.
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Highlights
• High glucose levels increased risk for dementia in diabetic patients.
• Glucose levels significantly declined as the patient progressed to dementia.
• These findings may represent a strong early metabolic indicator for dementia.
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Figure 1. 
Predicted mean glucose levels over time in diabetic participants diagnosed with dementia, 
mild cognitive impairment and normal cognition.
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Table 2
Results from final mixed effects model with repeated glucose levels over time as the dependent variable in 
participants without diabetes (n=1018).
Independent Variables Parameter Estimate Standard Error p-value
Female −3.1977 1.1252 0.0045
Time 0.4614 0.2228 0.0383
Group 0.6818
 MCI −0.9466 1.9256 0.6230
 Dementia 1.2008 1.8354 0.5130
 Normal ref    – –
Time2 0.04630 0.01650 0.0050
Group*time 0.0953
 MCI*time −0.3804 0.2053 0.0639
 Dementia*time 0.2115 0.2469 0.3917
 Normal*time ref – –
Alzheimers Dement. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hendrie et al. Page 15
Table 3
Results from mixed effects model with repeated glucose levels over time as the dependent variable in 
participants with diabetes (n=973).
Independent Variables Parameter Estimate Standard Error p-value
Female −6.8003 2.9223 0.0200
Age at baseline −0.5086 0.2329 0.0290
BMI −0.1361 0.2610 0.6021
Diabetes Meds
 Insulin only 8.7675 5.0160 0.0805
 Oral only −0.3222 3.7077 0.9308
 Both Oral and Insulin 15.7825 4.2845 0.0002
 None ref – –
Time 1.8708 0.8551 0.0287
Group 0.4511
 MCI −2.9185 4.6130 0.5270
 Dementia −7.1591 5.4719 0.1908
 Normal ref – –
BMI*time −0.08142 0.02732 0.0029
Group*time
 MCI*time −0.2691 0.4424 0.5430
 Dementia*time −2.1840 0.5819 0.0002
 Normal*time ref – –
Diabetes Meds*time
 Insulin only*Time −1.4708 0.4953 0.0030
 Oral only*Time −0.1862 0.3899 0.6329
 Both Oral and Insulin*Time −0.4650 0.4150 0.2626
 None*Time ref – –
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